Title: Treating Negative Symptoms in Schizophrenia: an Update
year: 2016
Journal: Curr Treat Options Psychiatry
Volume: 3
Pages: 133-150
Epubdate: 05/07/2016
Alternate Journal: Current treatment options in psychiatry
Legal note: PMC4908169
Article Number: 27376016
Keywords: Brain stimulation Negative symptoms Pharmacotherapy Schizophrenia Treatment
Abstract: Interest in the negative symptoms of schizophrenia has increased rapidly over the last several decades, paralleling a growing interest in functional, in addition to clinical, recovery, and evidence underscoring the importance negative symptoms play in the former. Efforts continue to better define and measure negative symptoms, distinguish their impact from that of other symptom domains, and establish effective treatments as well as trials to assess these. Multiple interventions have been the subject of investigation, to date, including numerous pharmacological strategies, brain stimulation, and non-somatic approaches. Level and quality of evidence vary considerably, but to this point, no specific treatment can be recommended. This is particularly problematic for individuals burdened with negative symptoms in the face of mild or absent positive symptoms. Presently, clinicians will sometimes turn to interventions that are seen as more "benign" and in line with routine clinical practice. Strategies include use of atypical antipsychotics, ensuring the lowest possible antipsychotic dose that maintains control of positive symptoms (this can involve a shift from antipsychotic polypharmacy to monotherapy), possibly an antidepressant trial (given diagnostic uncertainty and the frequent use of these drugs in schizophrenia), and non-somatic interventions (e.g., cognitive behavioral therapy, CBT). The array and diversity of strategies currently under investigation highlight the lack of evidence-based treatments and our limited understanding regarding negative symptoms underlying etiology and pathophysiology. Their onset, which can precede the first psychotic break, also means that treatments are delayed. From this perspective, identification of biomarkers and/or endophenotypes permitting earlier diagnosis and intervention may serve to improve treatment efficacy as well as outcomes.
Notes: Remington, Gary Foussias, George Fervaha, Gagan Agid, Ofer Takeuchi, Hiroyoshi Lee, Jimmy Hahn, Margaret Review Journal Article Switzerland Curr Treat Options Psychiatry. 2016;3:133-150. Epub 2016 Apr 8.
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908169/pdf/40501_2016_Article_75.pdf
URI: https://open-access.imh.com.sg/handle/123456789/5029
Authors Address: Department of Psychiatry, University of Toronto, Toronto, ON Canada ; Institute of Medical Science, University of Toronto, Toronto, ON Canada ; Centre for Addiction and Mental Health (CAMH), 250 College St., Toronto, ON M5T 1R8 Canada. Institute of Medical Science, University of Toronto, Toronto, ON Canada ; Centre for Addiction and Mental Health (CAMH), 250 College St., Toronto, ON M5T 1R8 Canada. Department of Psychiatry, University of Toronto, Toronto, ON Canada ; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan ; Centre for Addiction and Mental Health (CAMH), 250 College St., Toronto, ON M5T 1R8 Canada. Department of General Psychiatry 1, Institute of Mental Health, 10 Buangkok View, 539747 Singapore, Singapore ; Centre for Addiction and Mental Health (CAMH), 250 College St., Toronto, ON M5T 1R8 Canada.
Database Provider: NLM
language: eng
Appears in Collections:2016




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.